Generate a tailored SOP for Dr. Michael Zalutsky. Improve your application with a focused, well-structured draft.
Michael Zalutsky is a distinguished professor in the Departments of Radiology, Biomedical Engineering, Pathology, and Radiation Oncology at Duke University, with a specific focus on the development of novel radioactive compounds that improve the diagnosis and treatment of cancer. His research primarily involves radiohalogenation of biomolecules utilizing site-specific approaches, emphasizing demetallation reactions. Notably, he employs radionuclides in imaging, including I-123, I-124, and F-18, with a keen interest in their application in positron emission tomography to quantify biochemical and physiological processes in living humans. In therapeutic applications, he investigates astatine-211, which emits alpha particles capable of targeted cytotoxicity, presenting a significantly higher toxicity profile compared to conventional beta particle therapies. He has conducted groundbreaking work in developing agents for radioiodination and identifying strategies to enhance their efficacy, as well as focusing on the construction of monoclonal antibodies for targeting specific cancer types. Zalutsky's contributions to the field are recognized not only through his research achievements but also via his roles at the Duke Cancer Institute, where he continues to push the boundaries of radiopharmaceutical science and cancer therapy.
Department of Biomedical Engineering (MS program)